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Abstract
The purpose of this study was to study the effects of L-arginine on the clinical course and some immunological parameters in 
patients with asthma. Material and Methods:  In this study, we examined 56 patients with moderate and severe persistent asthma. The 
average duration of the disease was 15±2. 3 years. The patients were divided into two groups. The patients of the study group (n=25) 
were subjected to the standard treatment and nitric oxide (NO) donor L-arginine. The patients of the comparison group (n=31) received 
the standard treatment only. All patients underwent a complete physical examination including a determination of serum cytokine levels 
(IL-4, IL-8, and TNF-α) before and after treatment. Results:  In both groups, the baseline serum levels of IL-4, IL-8 and TNF-Fα were 
greater than the normative values. Direct correlations were observed between the level of the interleukins and clinical symptoms. Daily 
intravenous infusion of L-arginine at 4.2 g for 30 min over 10 days significantly reduced the serum levels of IL-4, IL-8 and TNF-α. No 
significant changes were noted in the levels of these parameters in the control group. Conclusion: The addition of L-arginine to the basic 
treatment in asthmatic patients contributed to the earlier improvement of clinical symptoms and a significant reduction of the IL-4, IL-8 
and TNF-α serum levels.
Key words: asthma, L-arginin, interleukins, endothelial dysfunction.
CLINICAL RESEARCH
Introduction
Asthma is a serious public health problem, occurring across 
the world, affecting people of all ages. Asthma is an inflammatory 
disorder  of  the  airways,  which  involves  several  inflammatory 
cells and multiple mediators that result in characteristic 
pathophysiological changes [1-3]. Cytokines orchestrate the 
inflammatory response in asthma and determine its severity [4]. 
The nitric oxide (NO) has also been identified as a key mediator 
of asthma [1]. NO has been well described in the literature as 
an important signaling molecule involved in regulation of 
many mammalian physiologic and pathophysiologic processes, 
particularly in the lung.  NO plays a role in regulation of both 
pulmonary vascular tone as well as airway bronchomotor tone 
through effects on relaxation of smooth muscle.  In addition, NO 
participates in inflammation and host defense against infection via 
alterations in vascular permeability, changes in epithelial barrier 
function and repair, cytotoxicity, upregulation of ciliary motility, 
altered mucus secretion, and inflammatory cell  infiltration [5,6].   
Many studies show that asthma is associated with 
endothelial dysfunction in the conducting airway that is invested 
by the systemic circulation, and that inhaled glucocorticosteroids 
restore endothelial function in these conditions. Endothelial 
dysfunction presumably is an expression of airway vascular 
inflammation  [7].  Endothelial  dysfunction,  expressed  during 
*Corresponding author:  Sayyora  A.  Bazarova,  Republican 
Specialized Scientific-Practical Medical Center of Therapy and Medical 
Rehabilitation. 4, Osiyo street, Yunusabad district, 100084, Tashkent, 
Republic of Uzbekistan. 
Tel: 99894 6531358. 
E-mail: d-sayyorik@mail.ru13 S. A. Bazarova et al. / International Journal of BioMedicine 3(1) (2013) 12-14
the early stages of the disease, exacerbates respiratory failure, 
hypoxemia and tissue hypoxia, as well as promotes systemic and 
pulmonary hemodynamic disorders [8]. 
The goal of asthma management strategy is to achieve 
and maintain clinical control. To treat asthma there are two 
classes of medications: controllers (inhaled and systemic 
glucocorticosteroids,  leukotriene modifiers, long-acting inhaled 
β2–agonists in combination with inhaled glucocorticosteroids, 
sustained-release theophylline, cromones, and anti-IgE)   
and  relievers  (rapid-acting  inhaled  β2–agonists, inhaled 
anticholinergics, short-acting theophylline,  and short-acting 
oral β2–agonists). Despite significant progress in the control of 
asthma, many problems of the drug therapy are not fully resolved.
Since  the  identification  of  nitric  oxide  as  a  bioactive 
molecule involved in the pathogenesis of pulmonary disorders, 
many researchers have focused on the importance of the nitric 
oxide synthase (NOS) pathway involving conversion of L-arginine 
to NO and L-citrulline.  L-arginine is produced from L-citrulline 
by cytosolic enzymes argininosuccinate synthetase 1 (ASS1) and 
argininosuccinate lyase (ASL). As the only substrate for NOS, 
L-arginine bioavailability plays a key role in determining NO 
production [5]. 
The purpose of this study was to study the effects of 
L-arginine on the clinical course and some immunological 
parameters in patients with asthma. 
Materials and Methods
We examined 56 patients aged from 18 to 55 years (mean 
age 38.5±4.2 years) with the moderate and severe persistent 
asthma. The patients were staged according to GINA [1]. The 
average duration of the disease was 15±2.3 years. The patients 
were divided into two groups. After giving informed consent, the 
patients were divided into two groups.  The patients of the study 
group (n=25) were subjected to the standard treatment and nitric 
oxide (NO) donor L-arginine. The patients of the comparison 
group (n=31) received the standard treatment only. The study was 
approved earlier by the Institutional Ethics Committee. 
L-arginine (Tivortin, URiA-PHARM, Ukraine) was 
administered daily by intravenous infusion at 4.2 g for 30 min over 
10 days. All patients underwent a complete physical examination 
including a determination of serum cytokine levels (IL-4, IL-8, 
and TNF-α) before and after treatment. 
To assess the clinical efficacy, the Asthma Control Criteria 
including daytime symptoms, activity limitation, nighttime 
symptoms, and the need for emergency preparations were 
employed [1]. Symptoms were assessed on a five-point system 
to test for severity. 
Serum cytokine levels were determined by ELISA. 
Commercial kits for IL-4, IL-8 and IFN-α measurement were 
purchased from Vector-Best (Novosibirsk, Russia). 
Results were statistically processed using the computer 
software package Microsoft Excel (“Packet Analysis”). 
Quantitative parameters are presented as mean±SD. Analysis 
of the distribution of values obtained was performed using the 
Kolmogorov-Smirnov test. For data with normal distribution, 
inter-group comparisons were performed using Student's t-test. A 
value of P<0.05 was considered statistically significant.
Results
In both groups, baseline serum levels of IL-4, IL-8 and 
TNF-α  were  greater  than  the  normative  values.  L-arginine 
addition to the basic treatment in patients with asthma contributed 
to  the  earlier  improvement  of  clinical  symptoms.  Significant 
improvement of the clinical symptoms in the study group patients 
was recorded on the 3 - 4th day of treatment (p<0.01), whereas 
in the control group, the positive trend was recorded only on the 
7 – 8th day and was not considered significant (Table 1). 
The addition of L-arginine to the basic treatment 
significantly reduced the serum levels of IL-4, IL-8 and TNF-α 
on the 10th day treatment (p<0.05). No significant changes were 
noted in the levels of these parameters in the control group. 
Direct correlations were observed between the levels of the 
interleukins and clinical symptoms. The addition of L-arginine to 
the basic treatment in asthmatic patients contributed to the earlier 
improvement of clinical symptoms and a significant reduction of 
the IL-4, IL-8 and TNF-α serum levels (Table 2).
Conclusion
Thus, this study showed that the addition of Tivortin to the 
basic treatment in patients suffering from moderate and severe 
persistent asthma contributed to the earlier improvement of the 
clinical symptoms, particularly showing significant reduction in 
the IL-4, IL-8 and TNF-α serum levels. The preliminary positive 
results warrant further study of the possible effectiveness of 
L-arginine in patients with asthma.
Table 1.
The dynamics of clinical symptoms during treatment
Symptoms
Study group        
(n= 25)
Comparison 
group (n=31)
before  after before after
Daytime symptoms 4 1* 4 3*,**
limitation of activities 3 -* 4 3*,**
Nocturnal symptoms 5 1* 5 4*,**
Need for reliever/rescue 
treatment 4 -* 4 2*,**
Note: *- р < 0.05 with initial data; **- р < 0.01 between groups.  
Table 2.
The dynamics of immunological parameters during treatment
Parameters
Study group   
    (n= 25)
Comparison group 
(n=31)
before  after before after
IL-4  (0–20 pg/mL) 68.3+1.2 34.7+0.4* 66.7+1.5 54.2+2.3*,**
IL-8  (0–10 pg/mL) 34.3+1.6 18.2+0.8* 34.2+1.1 25.4+2.1*,**
TNF-α (0–6 pg/mL) 18.1+1.4 11.3+0.2* 18.5+1.2 15.2+1.9*,**
Note: *- р < 0.05 with initial data; **- р < 0.01 between groups.  14                                                     S. A. Bazarova et al. / International Journal of BioMedicine 3(1) (2013) 12-14
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